August 15, 2025 04:16 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Can't ignore Pahalgam: Supreme Court on pleas seeking restoration of Jammu and Kashmir's statehood | Supreme Court reserves order on pleas challenging judgement on stray dogs, no stay issued | Pakistan: Three killed, 60 injured in aerial firing during Independence Day celebrations in Karachi | Supreme Court cancels Darshan Thoogudeepa and Pavithra Gowda's bail in Renukaswamy murder case | Shilpa Shetty, Raj Kundra booked for allegedly cheating Mumbai-based businessman of Rs. 60 crore | 'Terrorists will destroy it': Threatening message on Puri's Jagannath Temple wall triggers alarm | Sonia Gandhi's name featured in voters' list twice before she became Indian citizen: BJP on Rahul's opposition to SIR | Amid uproar, CJI assures examination of Supreme Court order on Delhi-NCR stray dogs | One soldier killed in gunfight along LoC in Jammu and Kashmir's Baramulla | 'Aadhaar not a proof of citizenship': Supreme Court backs Election Commission's argument over Bihar SIR
Pfizer-BioNTech
WIKIMEDIA COMMONS

Pfizer-BioNTech apply for US authorization to use Its vaccine in adolescents : Statement

| @indiablooms | Apr 10, 2021, at 04:08 pm

Washington/Sputnik: Pfizer and BioNTech said in a statement that they have applied to expand emergency use authorization of their vaccine for usage in adolescents between 12 and 15 years old.

"Pfizer Inc. and BioNTech SE today requested amendments to the US Emergency Use Authorization (EUA) of the Pfizer-BioNTech Vaccine (BNT162b2) to expand the use in adolescents 12 to 15 years of age," the statement said on Friday.

The EUA requests are based on the recent results of the concluded Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of the novel coronavirus that demonstrated 100 percent efficacy and strong antibody response after vaccination with the Pfizer-BioNTech vaccine.

In the coming days, the companies plan to request similar authorization by the regulatory authorities in other countries worldwide, the statement added.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Close menu